RE:RE:RE:In the meantime, Genting is moving upHere's some recent commentary on TauRx from a Genting analyst...
It is worth noting that Genting has a call option in its 20%-owned TauRx Pharmaceuticals Ltd, which is developing a drug to combat Alzheimer's disease.
It is understood that TauRx has submitted its lead investigative drug hydromethylthionine mesylate (HMTM) for consideration for approval in the UK via the Medicines and Healthcare Products Regulatory Agency.
“We currently value TauRx at only US$1 billion (RM4.65 billion). Our TP for Genting may be revised to over RM8 should TauRx be valued at US$15 billion as once widely reported,” said Maybank IB, which maintains its "buy" call for Genting with a higher TP of RM5.84 (from RM5.49).
https://theedgemalaysia.com/node/696539